IL-17 Affects the Progression, Metastasis, and Recurrence of Laryngeal Cancer via the Inhibition of Apoptosis through Activation of the PI3K/AKT/FAS/FASL Pathways

Figure 1

Western blotting analysis was used for time course analysis of IL-17, IL-17R, P-AKT, P-PI3K, FAS, and FASL protein expression in different pathological grades of LC tissues. (a) IL-17 and IL-17R protein expression in paracancerous tissues of the control group and different pathological grades of LC tissues. (b) P-AKT, P-PI3K, FAS, and FASL protein expression in paracancerous tissues of the normal control group and different pathological grades of LC tissues. The bar graph of protein quantification plotted from not <3 independent experiments. The band intensity of IL-17, IL-17R, P-AKT, P-PI3K, FAS, and FASL was quantified by densitometry and normalized to β-actin. Densitometry values in the histograms were expressed as fold change relative to the normal control, which was assigned a value of 1. compared with the control group. 1 = paracancerous tissues of the control group, 2 = well-differentiated group, 3 = moderately differentiated group, and 4 = poorly differentiated group. LC: laryngeal cancer. (c) LC, lymphocytic host response, and tumor infiltrative lymphocytes. (A) Arrows show paracancerous tissues of the control group with pushing invasive tumor front and band-like dense inflammatory infiltrates. H&E,400x. (B) Arrows show the well-differentiated group demonstrating minimal lymphocytic host response. H&E, 400x. (C) Arrows show the moderately differentiated group with a more intense lymphocytic host response. H&E, 400x. (D) Arrows show tumor-infiltrating lymphocytes in the poorly differentiated group. H&E, 400x. H&E: hematoxylin and eosin. (d) IHC analysis of IL-17 and IL-17R protein expression levels in LC tissues from patients at different pathologic grading. The (A–D) indicated IL-17 expression in LC tissues from patients with different pathologic grading. The (E–H) indicated IL-17R expression in LC tissues from patients with different pathologic grading. . .

(a)

(b)

(c)

(d)